Expert Patient Advocates & 21st

Century Therapies Forum

TORONTO NOVEMBER 19-20, 2015 CHANDER SEHGAL, MD, MBA DIRECTOR, CDR AND OPTIMAL USE

Role of CADTH

Health  Canada  asks:  Is  it  safe?  Does  it  

work?  

Patented  Medicine  Prices    Review  Board  asks:  

Is  the  price  excessive  compared  to  other  developed  countries?  

 

CADTH  asks:    How  does  it  compare  to  exis>ng    

treatment  op>ons?  

Federal,  provincial  &  

territorial  health  bodies  ask:  

Can  we  afford  it?  

 

18 publicly funded drug plans

serving  7.8  million  people  

1 pan-Canadian* process:

Conducting reviews of the clinical, cost-effectiveness, and

patient group input for drugs

Providing evidence-based formulary listing

recommendations

 *except  for  Quebec  

CADTH Common Drug Review

“I  am  very  aware  that  there  are  people  on  the  other  side  of  these  submissions.  There  are  families.  There  are  husbands,  wives,  partners,  children..…We  need  to  take  what  they’re  telling  us….  use  as  a  guiding  point  for  making  very  humane  decisions.”    

Cate  Dobhran,  CDEC  public  member  2014  

“PaBent  input  is  valuable  because  they  can  tell  us  things  no-­‐one  else  can……  Their  prioriBes  are  not  someBmes  the  prioriBes  people  presume,  or  assume,  they  are.”      Frank  Gavin,  CDEC  public  member  

Expert  CommiDees  (CDEC,  pERC)    

Pa>ent  input  presented,  used  in  delibera>ons  &  

reflected  in  recommenda>ons    

Use of patient input at CADTH

CADTH  Review  Team  Pa>ent  input  used  to  

inform  protocol  &  report  

Public  Drug  Plans  

Shared  with  plans  and  shared  at  www.cadth.ca  

Used to identify outcomes

Understand current therapies

Eculizumab  for  aHUS,  CDEC  Record  of  Advice  

Ro>go>ne  for  Idiopathic  Parkinson  Disease,    CDEC  Recommenda>on  

Understand expectations

Pirfenidone    for  Idiopathic  Pulmonary  Fibrosis,  CDEC  Recommenda>on  

Vimizim    for  Mucopolysaccharidosis  IVA,    CDEC  Recommenda>on  

Evolution & revolution •  2010: Patient Input to CDR begins

•  2013: Individual patient input in absence of patient group (pilot) •  2013: Public web posting of full CDR clinical report, economic report

& original patient input (Update 87)

•  2013: Creation CADTH Patient Community Liaison Forum

•  2014: Thank you feedback letters to patient groups begin

•  2014: Adjustments to existing CDR process for drugs for rare diseases, including additional appropriate specialists (Update 103)

•  2015: In-person & written consultations on CDR & pCODR alignment

•  2015: Consultation CDR & pCODR Recommendations Framework (Update 114)

Patient involvement in scientific advice

https://scientificadvice.cadth.ca/

Support for patient groups

youtube.com/CADTHACMTS

Pa>ent  Input  into  CADTH  Common  Drug  Review:  Video  Series  

pCODR    &  CCAN’s  Guide  for  Pa>ent  Advocacy  Groups:  Strengthening  your  submission    Pa>ent  Engagement  in  HTA:    Using  Pa>ent  Perspec>ves  to  Frame  HTAs  

Two  pa>ent  engagement  officers  at  CADTH,  available  to  answer  ques>ons  or  provide  guidance,    Sarah  Berglas  &  Tamara  Rader  

CADTH Patient Community Liaison Forum, including CORD

Embrace evolving successes in patient engagement practices in health technology assessment.

Implement greater transparency regarding methods, performance, impact, and projects in development.

Create ongoing process efficiencies to meet the demand for drug reviews and optimal use projects.

@CADTH_ACMTS linkedin.com/company/cadth

slideshare.net/CADTH-ACMTS youtube.com/CADTHACMTS

cadth.ca/photoblog requests@cadth.ca

Connect with us